Will Cannabigerol trigger neuroregeneration after a spinal cord injury? An in vitro answer from NSC-34 scratch-injured cells transcriptome

Spinal cord injury affects the lives of millions of people around the world, often causing disability and, in unfortunate circumstances, death. Rehabilitation can partly improve outcomes and only a small percentage of patients, typically the least injured, can hope to return to normal living conditions. Cannabis Sativa is gaining more and more interest in recent years, even though its beneficial properties have been known for thousands of years. Cannabigerol (CBG), extracted from C. Sativa, is defined as the "mother of all cannabinoids" and its properties range from anti-inflammatory to antioxidant and neuroprotection. Using NSC-34 cells to model spinal cord injury in vitro, our work evaluated the properties of CBG treatments in motorneurons regeneration. While pre-treatment can modulate oxidative stress, increasing antioxidant enzyme genes like Tnx1, decreasing on the other hand Nos1, post-treatment seems able to induce regeneration genes by triggering different pathways, like Gap43 via p53 acetylation by Ep300 and Ddit3 and Xbp1 via Bdnf signaling, along with cytoskeletal remodeling signaling genes Nrp1 and Map1b. Our results indicate CBG as a phytocompound worth to further investigations in the field of neuronal regeneration.